文献速递糖尿病肥胖与代谢综合征

GLP-1受体激动剂用于未确诊动脉粥样硬化性心血管疾病的2型糖尿病患者缺血性卒中预防

GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease.
PubMed 文献 · Diabetes Care · 2022-01-01

本研究基于台湾全民健康保险研究数据库1998至2018年数据,回顾性队列分析GLP-1受体激动剂(GLP-1RA)对未确诊动脉粥样硬化性心血管疾病的亚洲2型糖尿病患者缺血性卒中预防效果。GLP-1RA组与非GLP-1RA组各6534例,中位随访3年。整体缺血性卒中住院风险未显著降低(校正HR 0.69,95%CI 0.47-1.00,P=0.0506),但用药超过251天者风险显著降低(校正HR 0.28,95%CI 0.11-0.71),累积剂量>1784 mg与风险显著降低相关。

要点

  • GLP-1RA整体未显著降低缺血性卒中住院风险(校正HR 0.69,95%CI 0.47-1.00,P=0.0506)。
  • 用药超过251天者缺血性卒中住院风险显著降低(校正HR 0.28,95%CI 0.11-0.71)。
  • 累积剂量>1784 mg与缺血性卒中住院风险显著降低相关。

核心结论

  • 在未确诊动脉粥样硬化性心血管疾病但伴有血脂异常或高血压的亚洲2型糖尿病患者中,较长使用时间和较高剂量的GLP-1RA与缺血性卒中住院风险降低相关。

研究设计与样本

  • 回顾性队列研究,数据来自台湾全民健康保险研究数据库1998至2018年,随访至缺血性卒中住院发生,中位随访3年,GLP-1RA组与非GLP-1RA组各6534例。

主要发现

  • 约53%患者为女性,平均年龄49±12岁。
  • GLP-1RA使用者整体缺血性卒中住院风险未显著低于非使用者(校正HR 0.69,95%CI 0.47-1.00,P=0.0506)。
  • 研究期间用药超过251天的GLP-1RA使用者缺血性卒中住院风险显著低于非使用者(校正HR 0.28,95%CI 0.11-0.71)。
  • 较高累积剂量(>1784 mg)与缺血性卒中住院风险显著降低相关。
  • 按基线特征划分的亚组分析未显示GLP-1RA观察效应的显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We assessed the effect of glucagon-like peptide 1 receptor agonists (GLP-1RAs) on ischemic stroke prevention in the Asian population with type 2 diabetes (T2D) without established cardiovascular disease. RESEARCH DESIGN AND METHODS: This retrospective cohort study examined data obtained from the Taiwan National Health Insurance Research Database for the period from 1998 to 2018. The follow-up ended upon the occurrence of hospitalization for ischemic stroke. The median follow-up period was 3 years. The effect of GLP-1RA exposure time on the development of hospitalization for ischemic stroke was assessed. RESULTS: The GLP-1RA and non-GLP-1RA user groups both included 6,534 patients. Approximately 53% of the patients were women, and the mean age was 49 ± 12 years. The overall risk of ischemic stroke hospitalization for GLP-1RA users was not significantly lower than that for GLP-1RA nonusers (adjusted hazard ratio [HR] 0.69 [95% CI 0.47-1.00]; P = 0.0506), but GLP-1RA users with a >251-day supply during the study period had a significantly lower risk of ischemic stroke hospitalization than GLP-1RA nonusers (adjusted HR 0.28 [95% CI 0.11-0.71]). Higher cumulative dose of GLP-1 RAs (>1,784 mg) was associated with significantly lower risk of ischemic stroke hospitalization. The subgroup analyses defined by various baseline features did not reveal significant differences in the observed effect of GLP-1RAs. CONCLUSIONS: Longer use and higher dose of GLP-1 RAs were associated with a decreased risk of hospitalization for ischemic stroke among Asian patients with T2D who did not have established atherosclerotic cardiovascular diseases, but who did have dyslipidemia or hypertension.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Yang YS, Chen HH, Huang CN, et al. GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease. Diabetes Care. 2022. PMID: 35275992. doi:10.2337/dc21-1993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。